Fri Sep 26 11:26:57 UTC 2025: Here’s a summarized news article based on the provided text:

**Summary:**

Former President Donald Trump announced plans to impose significant tariffs on imported pharmaceutical drugs, kitchen/bathroom fixtures, upholstered furniture, and heavy trucks, effective October 1st. The proposed 100% tariff on branded pharmaceutical products aims to incentivize domestic manufacturing, with exemptions for companies actively building plants in the U.S. The move has sent shockwaves through global pharmaceutical markets, causing stock prices to dip for major companies in Europe, Asia, and Australia. While experts anticipate some impact, they also note that many companies already have or are developing US-based manufacturing capabilities to mitigate the tariffs. The pharmaceutical industry is warning that the tariffs could jeopardize future investments in US research and development.

**News Article:**

**Trump Announces 100% Tariffs on Imported Pharmaceuticals, Rattling Global Markets**

**Washington, D.C.** – Former President Donald Trump announced on Thursday a sweeping set of tariffs targeting imported goods, including a staggering 100% levy on branded and patented pharmaceutical products. The tariffs, slated to take effect on October 1st, are aimed at bolstering domestic manufacturing, with exemptions for companies actively building pharmaceutical plants within the United States.

“Starting October 1, the United States will impose a 100 percent tariff on any branded or patented pharmaceutical product,” Trump stated on his Truth Social platform. He added that exceptions would be made for companies already “breaking ground” or “under construction” on US manufacturing facilities.

The move has sent ripples through global pharmaceutical markets. Shares in major pharmaceutical companies in Switzerland, Germany, Japan, and Australia experienced declines following the announcement. In India, the main pharmaceuticals index slid by 2 percent.

The US heavily relies on imports for its pharmaceutical supply, with significant contributions from Ireland, Switzerland, Germany, and India. In 2023, the US imported approximately $158 billion worth of pharmaceutical products, including $86.4 billion in packaged medicaments.

While experts predict some disruption, they also suggest that the long-term impact may be mitigated by the existing and expanding US-based manufacturing capabilities of many major pharmaceutical companies. “All major players have some production presence domestically and almost all have announced increased investment directly tied towards local manufacturing,” said Jared Holz, a healthcare equity specialist at Mizuho Securities.

However, the Pharmaceutical Research and Manufacturers of America (PhRMA) is warning that the tariffs could have unintended consequences. “Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” warned PhRMA Senior Vice President Alex Schriver.

In addition to pharmaceuticals, Trump also announced tariffs of 50% on kitchen cabinets, bathroom vanities, and associated products, 30% on upholstered furniture, and 25% on heavy trucks, also taking effect on October 1st. He cited the need to protect US manufacturing processes due to “large-scale flooding” of these products into the US.

The tariffs represent a significant shift in US trade policy and have sparked debate about their potential impact on consumers, businesses, and the global economy.

Read More